<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-04-13T19:42:53Z</responseDate><request verb="GetRecord" identifier="oai:www.recercat.cat:2445/192211" metadataPrefix="qdc">https://recercat.cat/oai/request</request><GetRecord><record><header><identifier>oai:recercat.cat:2445/192211</identifier><datestamp>2025-12-04T21:12:52Z</datestamp><setSpec>com_2072_1057</setSpec><setSpec>col_2072_478781</setSpec><setSpec>col_2072_478917</setSpec></header><metadata><qdc:qualifieddc xmlns:qdc="http://dspace.org/qualifieddc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://purl.org/dc/elements/1.1/ http://dublincore.org/schemas/xmls/qdc/2006/01/06/dc.xsd http://purl.org/dc/terms/ http://dublincore.org/schemas/xmls/qdc/2006/01/06/dcterms.xsd http://dspace.org/qualifieddc/ http://www.ukoln.ac.uk/metadata/dcmi/xmlschema/qualifieddc.xsd">
   <dc:title>Does Dietary Coenzyme Q10 plus Selenium Supplementation Ameliorate Clinical Outcomes by Modulating Oxidative Stress and Inflammation in Individuals with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome?</dc:title>
   <dc:creator>Castro-Marrero, Jesús</dc:creator>
   <dc:creator>Domingo i Pedrol, Joan Carles</dc:creator>
   <dc:creator>Cordobilla, Begoña</dc:creator>
   <dc:creator>Ferrer, Roser</dc:creator>
   <dc:creator>Giralt, Marina</dc:creator>
   <dc:creator>Sanmartín-Sentañes, Ramon</dc:creator>
   <dc:creator>Alegre-Martín, José</dc:creator>
   <dc:subject>Sistema cardiovascular</dc:subject>
   <dc:subject>Coenzims</dc:subject>
   <dc:subject>Síndrome de fatiga crònica</dc:subject>
   <dc:subject>Inflamació</dc:subject>
   <dc:subject>Encefalomielitis</dc:subject>
   <dc:subject>Seleni</dc:subject>
   <dc:subject>Cardiovascular system</dc:subject>
   <dc:subject>Coenzymes</dc:subject>
   <dc:subject>Chronic fatigue syndrome</dc:subject>
   <dc:subject>Inflammation</dc:subject>
   <dc:subject>Encephalomyelitis</dc:subject>
   <dc:subject>Selenium</dc:subject>
   <dcterms:abstract>Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a neuroinflammatory, multifaceted chronic disorder of unknown cause. Accumulating data indicate a link between a redox imbalance, mitochondrial dys-function, and inflammation status in ME/CFS. Coenzyme Q10 (CoQ10) and selenium as effective antioxi-dant and anti-inflammatory agents have shown potential clinical implications in chronic diseases; however, their therapeutic benefits in ME/CFS remain elusive. This open-label exploratory study aimed to evaluate the effec- tiveness of combined CoQ10 plus selenium supplementation on clinical features and circulating biomarkers in ME/CFS. Twenty-seven ME/CFS patients received an oral combination of 400 mg of CoQ10 and 200 lg of selenium daily for 8 weeks. The primary endpoint was patient-reported changes in outcome measures from baseline to 8 weeks' postintervention. Secondary endpoint included changes in circulating biomarkers from base-line to each participant. After an 8-week intervention, a significant improvement was found for overall fatigue severity ( p = 0.021) and global quality of life ( p = 0.002), while there was no significant effect on the sleep dis-turbances ( p = 0.480) among participants. After 8 week's intervention, there was significantly increased total antioxidant capacity, and there were reduced lipoperoxide levels from the participants ( p &lt; 0.0001 for both). Circulating cytokine levels decreased significantly ( p &lt; 0.01 for all), but with no significant changes in the C-reactive protein, FGF21, and NT-proBNP biomarkers after supplementation. Based on these findings, we hypo-thesized that long-term supplementation of combined CoQ10 and selenium may indicate a potentially beneficial synergistic effect in ME/CFS. Antioxid. Redox Signal. 36, 729-739.</dcterms:abstract>
   <dcterms:issued>2023-01-17T10:02:54Z</dcterms:issued>
   <dcterms:issued>2023-01-17T10:02:54Z</dcterms:issued>
   <dcterms:issued>2022</dcterms:issued>
   <dcterms:issued>2023-01-17T10:02:54Z</dcterms:issued>
   <dc:type>info:eu-repo/semantics/article</dc:type>
   <dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
   <dc:relation>Reproducció del document publicat a: https://doi.org/10.1089/ars.2022.0018</dc:relation>
   <dc:relation>Antioxidants &amp; Redox Signaling, 2022, vol. 36, num. 10-12, p. 729-739</dc:relation>
   <dc:relation>https://doi.org/10.1089/ars.2022.0018</dc:relation>
   <dc:rights>cc by (c) Castro-Marrero, Jesús et al., 2022</dc:rights>
   <dc:rights>http://creativecommons.org/licenses/by/3.0/es/</dc:rights>
   <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
   <dc:publisher>Mary Ann Liebert</dc:publisher>
   <dc:source>Articles publicats en revistes (Bioquímica i Biomedicina Molecular)</dc:source>
</qdc:qualifieddc></metadata></record></GetRecord></OAI-PMH>